8-K

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

FORM 8-K

CURRENT REPORT
Pursuant to Section 13 or 15(d) of

the Securities Exchange Act of 1934

Date of report (Date of earliest event reported)               March 29, 2007

INSPIRE PHARMACEUTICALS, INC.

(Exact Name of Registrant as Specified in Charter)

     Delaware                                    000-31135                            04-3209022
(State or Other Jurisdiction(Commission        (IRS Employer
of Incorporation)                            File Number) Identification No.)

4222 Emperor Boulevard, Suite 200, Durham, North Carolina            27703-8466
(Address of Principal Executive Offices)(Zip Code)

Registrant's telephone number, including area code          (919) 941-9777

_____________________________________________
(Former Name or Former Address, if Changed Since Last Report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

[ ] Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

[ ] Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

[ ] Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

[ ] Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Item 5.05    Amendments to the Registrant's Code of Ethics, or Waiver of a Provision of the
                    Code of Ethics.

         On March 29, 2007, Inspire Pharmaceuticals, Inc. ("Inspire") adopted a new Code of Conduct and Business Ethics (the "Code of Ethics") governing the conduct of its directors, officers and employees, including each of its principal executive officer, principal financial officer and principal accounting officer.

        The new Code of Ethics, which will become effective on April 16, 2007, consolidates and restates the provisions of the Inspire Code of Business Ethics and the Inspire Code of Ethics and Conduct Relating to Financial Affairs (collectively, the "Prior Codes of Ethics"), which overlap one another in substantive scope. In order to consolidate the subject matter of the Prior Codes of Ethics, Inspire has replaced them with the new Code of Ethics, which retains all of the material elements embedded within the Prior Codes of Ethics and includes additional procedures to be followed for the approval of prospective related person transactions and additional methods for reporting possible violations of the Code of Ethics. These additional provisions are described in further detail below.

        The Code of Ethics sets forth specific mandatory procedures that must be followed for the approval of related person transactions. As required by the Prior Codes of Ethics with respect to any potential conflict of interest generally, the Code of Ethics mandates that any proposed related person transaction involving a director, executive officer or 5% or greater stockholder of Inspire, or an immediate family member thereof, be submitted for review to Inspire's Corporate Compliance Officer and an executive officer or director of Inspire. The Code of Ethics further requires that the Audit Committee of Inspire's Board of Directors approve a proposed related person transaction in advance.

        The Code of Ethics provides additional options to directors, officers and employees of Inspire to report possible violations of the Code of Ethics in one of a number of fashions. The Code of Ethics maintains the general procedure included in the Prior Codes of Ethics, whereby enforcement of compliance and reporting of violations are generally channeled through Inspire's Corporate Compliance Officer. The Code of Ethics allows personnel to make reports to the following persons: (i) the Chairman of the Audit Committee of the Board of Directors; (ii) any executive officer of Inspire; and (iii) an independent firm, Ethical Advocate. Reports made to Ethical Advocate may be made either anonymously or on a named basis, via either its website or by calling a toll free hotline.

        The Code of Ethics, which is attached to this Current Report on Form 8-K as Exhibit 14.1, will be posted on Inspire's website (www.inspirepharm.com) on or about April 16, 2007, the effective date of the Code of Ethics.

Item 9.01     Financial Statements and Exhibits.

(d)   Exhibits.

No.            Description

14.1           Code of Conduct and Business Ethics, adopted by Inspire Pharmaceuticals, Inc. on
                  March 29, 2007.

SIGNATURE

        Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

                                                                       Inspire Pharmaceuticals, Inc.

By: /s/   Joseph M. Spagnardi                             
      Joseph M. Spagnardi,
      Senior Vice President, General Counsel
      and Secretary

Dated: April 4, 2007

EXHIBIT INDEX

No.            Description

14.1           Code of Conduct and Business Ethics, adopted by Inspire Pharmaceuticals, Inc. on
                  March 29, 2007.

EX-14.1

Inspire Pharmaceuticals, Inc.

Code Of Conduct and Business Ethics

Adopted: March 29, 2007 Page 1 of 5

        The Board of Directors of Inspire Pharmaceuticals, Inc. (the "Company" and "Inspire") has adopted this Code of Ethics (this "Code") to:

• define the Company's expectations for the ethical conduct of its business;

• promote honesty and fair dealing, including the ethical handling of actual or apparent conflicts of interest;

• promote full, fair, accurate, timely and understandable disclosure of relevant Company information;

• promote compliance with applicable laws, rules and regulations, including, but not limited to, the rules of (i) the United States Securities and Exchange Commission; (ii) the National Association of Securities Dealers; and (iii) generally accepted accounting principles;

• encourage prompt reporting of violations of this Code; and

• deter wrongdoing and create accountability for adherence to this Code.

Inspire's officers, directors, employees, and other individuals in comparable capacities (collectively, "Company Personnel") are expected to be familiar with this Code and to adhere to the principles and procedures set forth herein. Additional policies and procedures of the Company include, but are not limited to, (i) the Code of Conduct: Promotional Interactions with Health Care Professionals, (ii) the Disclosure Policy, (iii) the Whistleblower Policy, and (iv) the Policy Statement Regarding Insider Trading. Company Personnel should be familiar with the policies and procedures set forth in these documents, as well as all other policies and procedures, applicable to their conduct. For questions regarding this Code, the initial contact person is the Company's Corporate Compliance Officer, Brian Kaufman. The persons serving as the Company's Corporate Compliance Officer, directors, and executive officers may change from time to time, and shall be identified on the Company's website located at www.inspirepharm.com.

        Company Personnel owe a duty to the Company to act with integrity. Integrity requires, among other things, being honest and candid while still maintaining the confidentiality of information where required or consistent with the Company's policies. Deceit and subordination of principle are inconsistent with integrity. In addition, acting with integrity requires that we observe both the form and spirit of laws and governmental rules and regulations, accounting standards and Company policies and that we adhere to a high standard of business ethics.

I.        Conflicts of Interest

        Company Personnel should avoid actual conflicts of interest and the appearance of conflicts of interest. A "conflict of interest" occurs when an individual's private interest is not aligned with the interests of the Company. A conflict of interest can arise when an individual takes actions or has interests, either directly or indirectly (including the interests of immediate family members), that compromise the performance of his or her duties to the Company. Put another way, the interests of the Company should never be subordinated to personal gain or advantage.

        In particular, clear conflict of interest situations involving Company Personnel who occupy supervisory positions or who have discretionary authority in dealing with a third party may include, among others:

• any significant ownership interest in, or financial arrangement with, any supplier, customer, development partner or competitor of the Company;
  
• any consulting or employment relationship with any supplier, customer, development partner or competitor of the Company;

• any outside business activity that detracts from an individual's ability to devote appropriate time and attention to his or her responsibilities with the Company;

• the receipt, either by Company Personnel or their families, of non-nominal gifts or excessive entertainment from any company or individual with which the Company has current or prospective business dealings; and

• selling anything to the Company or buying anything from the Company, except on the same terms and conditions as a third party.

        Any proposed transaction or relationship that could reasonably be expected to give rise to a conflict of interest, or the appearance of a conflict of interest, must be discussed with the Corporate Compliance Officer and an executive officer or director, as soon as possible and in any event prior to the date that the relationship is created or the transaction is entered into by the Company and such person(s).

        In any of the above circumstances involving "Related Persons," as defined below, such transactions or relationships must also be reviewed by the Company's Audit Committee, in accordance with current law, Nasdaq rules and regulations, and U.S. GAAP. For the purposes of this Code, a "Related Person" includes any director of the Company, executive officer of the Company, holder of more than 5% of the Company's stock or immediate family member of any such person. In each such case, the person involved will work with the Corporate Compliance Officer, the executive officers or directors, as appropriate, to monitor the conflict of interest (or appearance thereof) and assure that the individual who has the conflict is acting in the best interest of the Company and its stockholders.

II.        Disclosure

        Anyone involved in the Company's disclosure process is required to be familiar with and comply with the Company's Disclosure Policy. Additionally, such persons must ensure that the Company's public reports and documents comply in all material respects with the applicable federal securities laws. Supervisory personnel should, to the extent appropriate within his or her area of responsibility, consult with other Company officers and employees and take other appropriate steps regarding these disclosures with the goal of making full, fair, accurate, timely and understandable disclosure.

Company Personnel who are involved in the Company's disclosure process must:

• be familiar with the disclosure requirements applicable to the Company as well as the business and financial operations of the Company;

• not knowingly misrepresent, or cause others to misrepresent, facts about the Company to others, whether within or outside the Company, including to the Company's independent registered public accounting firm, governmental regulators and self-regulatory organizations; and

• properly review and critically analyze proposed disclosure for accuracy and completeness (or, where appropriate, delegate this task to others).

III.Accurate Reporting of Company Information

        It is the Company's goal to keep accurate business records to make sure that those records reflect actual transactions and payments in its system of internal controls. Facts should be recorded and reported accurately, honestly, and objectively. Company Personnel shall not hide or fail to record any funds, assets, or transactions. Furthermore, such persons shall be accurate and honest in reporting or recording the Company's business expenses, time worked, research test results, production data, expense reports, and all other business-related activities.

IV.       Confidential Business Information

        Company Personnel who learn of confidential business information about Inspire or other companies or persons with whom Inspire does business, shall keep such information confidential, and shall not disclose such information to third parties without first receiving the proper authority to do so.

V.         Contracts with Third Parties

        The Company sometimes uses outside people or organizations to help conduct its business and act on its behalf. Where the actions of such third parties may impact matters described in this Code, Company Personnel should make the third parties aware of this Code and ensure compliance herewith. They may be called agents, consultants, independent contractors, distributors, suppliers, or the like.

VI.       Fairness in Competitive Activity

        Company Personnel shall not discuss the following with competitors: prices or pricing policies (past, present and future), bids, discounts, promotions, costs, profits, customers, territorial markets, production capacities or plans, distribution or selling strategies, pending research, and the like. The Company shall not use unfair or deceptive acts or practices, including false or misleading advertising, or any other form of misrepresentation.

VII.      Gifts and Entertainment

        Although Company Personnel may occasionally exchange modest business courtesies with customers and suppliers, such activities should not be so substantial as to create the appearance of attempting to influence purchasing decisions or contracting decisions. Company Personnel shall not accept or give any gifts in the form of cash or cash equivalents. In addition to the foregoing, special rules governing gifts and business courtesies made in connection with the promotion of the Company's products are included in our Code of Conduct: Promotional Interactions with Health Care Professionals.

VIII.   Prohibition against Bribes, Kickbacks, Unlawful Payments, and Other Corrupt Practices

        All of the Company's products shall be marketed and sold solely on the basis of price, quality, and service. We do not offer, make, or authorize payment of money or anything of value, directly or indirectly, in order to:

1) Illegally influence the judgment or conduct, or create a desired outcome or action by, any individual, customer, company or company representative; or

2) Obtain or retain business, or influence any act or decision of a government official, political party, or candidate for political office.

        In addition to this Code, Company Personnel should become aware of the laws and regulations relating to the conduct of business in the pharmaceutical industry, including those relating to fraud and abuse, patient and privacy protection, and quality of health care services.

IX.      Reporting and Accountability

        The Board of Directors is ultimately responsible for applying and interpreting this Code in any particular situation. Company Personnel who become aware of an existing or potential violation of this Code shall notify the Corporate Compliance Officer promptly. Failure to report a violation of this Code is itself a violation of the Code. In the event an individual believes that the Corporate Compliance Officer is involved in a violation of this Code, the Chief Executive Officer and General Counsel should be notified as soon as possible.

        If Company Personnel are uncomfortable speaking with the Corporate Compliance Officer about a violation of the Code; such persons may contact Ken Lee, the Chairman of the Audit Committee of the Board of Directors or any executive officer. Company Personnel may also submit a report regarding a matter confidentially through an independent firm, Ethical Advocate, using either its website or toll free hotline. A report may be made anonymously or on a named basis as chosen by the reporting person. In order to submit a matter via the website Company Personnel will need to follow directions for creating an account and submitting a report, which are contained on the website located at:

        http://www.ethicaladvocate.com

Reports may also be submitted by calling the Ethical Advocate Hotline toll-free at:

        Ethical Advocate Hotline

        (866) 616-1749

        In accordance with the Inspire Pharmaceuticals, Inc. Whistleblower Policy, no one may retaliate against any person for good faith reports of potential violations of this Code.

X.       Waiver

        From time to time, the Company may in limited circumstances waive some provisions of this Code to address equitable concerns raised to the Board of Directors. Such waivers will not be granted unless truly necessary and warranted, and will only be done in a limited and qualified manner. Any waiver of this Code for executive officers or directors of the Company may be made only by the Board of Directors and must be promptly disclosed as required by Securities and Exchange Commission and the rules of the Nasdaq Stock Market. Any waiver for other employees may be made only by the Board of Directors or a committee of the Board of Directors comprised solely of independent directors.

DECISION TESTS

When trying to make a decision or determine an appropriate course of action involving the principles set forth herein, Company Personnel should ask themselves:

• Is my action honest and truthful?

• Is my action ethical and legal?

• Does my action comply with Inspire's policies and procedures, as well as with the spirit of its policies and procedures?

• How would my action look in the newspaper or on television? Would it appear to be improper, or make me feel embarrassed?